Timothy Huyck - Nebraska Cancer Specialists

Dr. Timothy Huyck

Claim this profile

Nebraska Methodist Hospital

Studies Pancreatic Cancer
Studies Colorectal Cancer
15 reported clinical trials
31 drugs studied

Area of expertise

1Pancreatic Cancer
Timothy Huyck has run 5 trials for Pancreatic Cancer. Some of their research focus areas include:
Stage IV
BRCA1 positive
BRCA2 positive
2Colorectal Cancer
Timothy Huyck has run 4 trials for Colorectal Cancer. Some of their research focus areas include:
Stage III
Stage IV
MLH1 positive

Affiliated Hospitals

Image of trial facility.
Nebraska Methodist Hospital
Image of trial facility.
Nebraska Cancer Specialists/Oncology Hematology West PC - MECC

Clinical Trials Timothy Huyck is currently running

Image of trial facility.

Chemotherapy + Immunotherapy

for Esophageal and Gastric Cancer

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma. The usual approach for patients is treatment with FOLFOX chemotherapy. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Fluorouracil stops cells from making DNA and it may kill tumor cells. Leucovorin is used with fluorouracil to enhance the effects of the drug. Oxaliplatin works by killing, stopping, or slowing the growth of tumor cells. Some patients also receive an immunotherapy drug, nivolumab, in addition to FOLFOX chemotherapy. Immunotherapy may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Irinotecan blocks certain enzymes needed for cell division and DNA repair, and it may kill tumor cells. Adding irinotecan to the FOLFOX regimen could shrink the cancer and extend the life of patients with advanced gastroesophageal cancers.
Recruiting2 awards Phase 32 criteria
Image of trial facility.

Observation

for Non-Small Cell Lung Cancer

GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Recruiting1 award N/A10 criteria

More about Timothy Huyck

Clinical Trial Related2 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Timothy Huyck has experience with
  • Fluorouracil
  • Gemcitabine
  • Oxaliplatin
  • Irinotecan Hydrochloride
  • Leucovorin Calcium
  • Cisplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Timothy Huyck specialize in?
Is Timothy Huyck currently recruiting for clinical trials?
Are there any treatments that Timothy Huyck has studied deeply?
What is the best way to schedule an appointment with Timothy Huyck?
What is the office address of Timothy Huyck?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security